← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Metallopharm, Llc
Delaware, OH
$3,108,003
Total funding
5
Grants
Funding over time
peak $844K · FY2007–16$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,108,003 · 5
By mechanism
R44$1,957,389 · 1
R43$925,746 · 3
N43$224,868 · 1
Investigators at Metallopharm, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection$844,040
R44 · FY2011 · AA
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection$813,038
R44 · FY2012 · AA
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection$300,311
R44 · FY2013 · AA
Rapid point-of-care diagnosis of wound infection$224,974
R43 · FY2016 · NR
CAPREOMYCIN: FORMULATION FOR ORAL DELIVERY$224,868
N43 · FY2014 · AI
Metallodrugs Targeting HCV Protease$222,025
R43 · FY2009 · AA
Metallodrugs Targeting HCV Protease$222,025
R43 · FY2010 · AA
Novel Engineered Synthetic Metallodrugs Directed Against HCV$156,722
R43 · FY2007 · AA
Novel Engineered Synthetic Metallodrugs Directed Against HCV$100,000
R43 · FY2008 · AA